Our study has some limitations that should be pointed out, as follows: first, the small sample size; second, the retrospective nature, which may be associated with selection bias and incomplete data, potentially affecting the generalizability and strength of the findings; third, the inclusion of a subset of patients who underwent transsphenoidal surgery prior to dopamine agonist initiation, which may have introduced confounding factors due to postsurgical modifications in prolactin levels, tumor volume, and treatment responsiveness. Here, PRL is linked to neoplasm.